BR112019021824A2 - Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio - Google Patents

Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio Download PDF

Info

Publication number
BR112019021824A2
BR112019021824A2 BR112019021824-6A BR112019021824A BR112019021824A2 BR 112019021824 A2 BR112019021824 A2 BR 112019021824A2 BR 112019021824 A BR112019021824 A BR 112019021824A BR 112019021824 A2 BR112019021824 A2 BR 112019021824A2
Authority
BR
Brazil
Prior art keywords
sporozoyte
plasmode
fragment
sequence
binding antibodies
Prior art date
Application number
BR112019021824-6A
Other languages
English (en)
Inventor
Lanzavecchia Antonio
Hoong Yu Tan Joshua
Daubenberger Claudia
Sack Brandon
Original Assignee
Institute For Research In Biomedicine
Seattle Children's Hospital D/B/A Seattle Children's Research Institute
Schweizerisches Tropen- Und Public Health-Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute For Research In Biomedicine, Seattle Children's Hospital D/B/A Seattle Children's Research Institute, Schweizerisches Tropen- Und Public Health-Institut filed Critical Institute For Research In Biomedicine
Publication of BR112019021824A2 publication Critical patent/BR112019021824A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção refere-se a fragmento da proteína circunsporozoíta do plasmódio de acordo com a seq id no: 1, por exemplo, para utilização em uma vacina contra a malária. a presente invenção também fornece ácidos nucleicos que codificam um fragmento da proteína circunsporozoíta do plasmódio de acordo com a seq id no: 1, composições que compreendem um fragmento da proteína circunsporozoíta do plasmódio de acordo com a seq id no: 1 e anticorpos de ligação a um fragmento da proteína circunsporozoíta do plasmódio de acordo com a seq id no: 1. os anticorpos de acordo com a presente invenção especificamente se ligam aos esporozoítos de p. falciparum e podem ser utilizados no tratamento e/ou prevenção da malária.
BR112019021824-6A 2017-04-19 2018-04-19 Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio BR112019021824A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487266P 2017-04-19 2017-04-19
US62/487,266 2017-04-19
PCT/EP2018/060113 WO2018193063A2 (en) 2017-04-19 2018-04-19 Novel malaria vaccines and antibodies binding to plasmodium sporozoites

Publications (1)

Publication Number Publication Date
BR112019021824A2 true BR112019021824A2 (pt) 2020-06-02

Family

ID=62063036

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019021824-6A BR112019021824A2 (pt) 2017-04-19 2018-04-19 Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio

Country Status (11)

Country Link
US (1) US20200093909A1 (pt)
EP (1) EP3612562A2 (pt)
JP (2) JP7278259B2 (pt)
KR (1) KR102595238B1 (pt)
CN (1) CN110945022B (pt)
AU (1) AU2018253918A1 (pt)
BR (1) BR112019021824A2 (pt)
CA (1) CA3058979A1 (pt)
EA (1) EA201992434A1 (pt)
SG (1) SG11201909265QA (pt)
WO (1) WO2018193063A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110168093B (zh) * 2017-09-12 2023-08-15 中科蓝华(广州)生物医药技术有限公司 一种转染细胞内寄生虫的试剂盒及其应用
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
EP3773708A2 (en) * 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
WO2020227228A2 (en) * 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2021001351A1 (en) * 2019-07-01 2021-01-07 Deutsches Krebsforschungszentrum Plasmodium antibodies
WO2021016509A1 (en) * 2019-07-24 2021-01-28 Unm Rainforest Innovations Malaria immunogen and methods for using same
WO2021068080A1 (en) * 2019-10-09 2021-04-15 The Hospital For Sick Children Immunogenic peptides, compositions, and methods for the treatment and/or prevention of malaria
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
WO2022027107A1 (en) * 2020-08-06 2022-02-10 Macfarlane Burnet Institute For Medical Research And Public Health Limited Immunogenic compositions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US20030119733A1 (en) * 1992-09-17 2003-06-26 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
HU219810B (hu) 1993-11-17 2001-08-28 Deutsche Om Arzneimittel Gmbh. Glükózamin-diszacharidok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények, valamint alkalmazásuk
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6207242B1 (en) 1995-12-28 2001-03-27 Hoffman Environmental System, Inc. Laminated package with enhanced interior and exterior
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
ES2314042T3 (es) 2001-04-17 2009-03-16 Dainippon Sumitomo Pharma Co., Ltd. Derivados nuevos de adenina.
PT1719511E (pt) 2001-11-16 2009-03-06 Coley Pharm Group Inc N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
CN101190946A (zh) * 2006-12-01 2008-06-04 中国人民解放军第二军医大学 重组恶性疟原虫环子孢子表面蛋白及其制法和用途
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
US20130323275A1 (en) * 2010-10-10 2013-12-05 Aduro Biotech Methods and compositions for inducing a t-cell response to plasmodium species
US20150359869A1 (en) * 2012-08-15 2015-12-17 Cyvax, Inc. Methods and compositions for preventing a condition

Also Published As

Publication number Publication date
WO2018193063A2 (en) 2018-10-25
JP2023058633A (ja) 2023-04-25
CA3058979A1 (en) 2018-10-25
AU2018253918A1 (en) 2019-10-31
CN110945022A (zh) 2020-03-31
KR102595238B1 (ko) 2023-10-26
EA201992434A1 (ru) 2020-03-30
CN110945022B (zh) 2024-04-05
WO2018193063A3 (en) 2019-01-03
SG11201909265QA (en) 2019-11-28
EP3612562A2 (en) 2020-02-26
JP7278259B2 (ja) 2023-05-19
KR20200141917A (ko) 2020-12-21
JP2020520674A (ja) 2020-07-16
US20200093909A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
BR112019021824A2 (pt) Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio
EA201792501A1 (ru) Вакцины для лечения и профилактики рака
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX2019003298A (es) Proteinas de union recombinantes y sus usos.
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
BR112015001390A2 (pt) vacina de proteína de fusão multimérica e imunoterápicos
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
BR112015013004A2 (pt) molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo
BR112018076234A2 (pt) vacina contra o vírus da bronquite infecciosa
WO2017142843A8 (en) Novel antigen for use in malaria vaccine
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2016010259A (es) Construcciones de variantes de sirp-alfa y sus usos.
EP3103471A3 (en) Acinetobacter baumanii antigens and the uses thereof
BR112016016103A2 (pt) Composição de antígenos micobacterianos
MX2021013252A (es) Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos.
MX2017012389A (es) Vacuna del virus de la parotiditis recombinante jeryl lynn2.
IN2014DN09445A (pt)
MX2018013524A (es) Antígenos de consenso de filovirus, construcciones de ácido nucleico y vacunas realizadas a partir de estos, y métodos para utilizarlos.
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
CO2018000255A2 (es) Polipéptido quimérico, vacuna contra la babesiosis, métodos de detección y kit
BR112016012285A2 (pt) composições imunogênicas e vacinas derivadas de proteínas receptoras de superfície bacteriana

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]